Top of this page
Skip navigation, go straight to the content

 

Pipeline

12 large and small molecules in clinical development
spanning 16 different types of diseases, from osteoporosis and multiple sclerosis to early-stage Parkinson’s, restless legs syndrome and rheumatoid arthritis.

  • 5 large, antibody-based molecules
  • 7 small, chemically-derived molecules

A broad range of molecules in late research and pre-clinical development.

CNS Indications Phase 1 Phase 2 Phase 3 Filed
Vimpat® epilepsy adjunctive therapy (EU) phase 1
Vimpat® diabetic neuropathic pain (EU) phase 1
Vimpat® diabetic neuropathic pain (US) phase 1
Vimpat® epilepsy adjunctive therapy (US) phase 1
Neupro® restless legs syndrome (EU) phase 1
Neupro® restless legs syndrome (US) phase 1
Neupro® advanced Parkinson’s disease (US) phase 1
Keppra® XR epilepsy (US) phase 1
Keppra® XR Epilepsy Monotherapy (US) phase 1
Vimpat® epilepsy monotherapy (US) phase 1
brivaracetam epilepsy phase 1
brivaracetam Unverricht Lundborg Disease (ULD) phase 1
Xyrem® fibromyalgia phase 1
lacosamide fibromyalgia phase 1
lacosamide migraine prophylaxis phase 1
rotigotine fibromyalgia phase 1
rotigotine nasal spray restless legs syndrome phase 1
CDP323 multiple sclerosis phase 1
Inflammation Indications Phase 1 Phase 2 Phase 3 Filed
Cimzia® Crohn’s disease (EU) phase 1
Cimzia® rheumatoid arthritis (US) phase 1
Cimzia® rheumatoid arthritis (EU) phase 1
Cimzia® psoriasis phase 1
epratuzumab systemic lupus erythematosus phase 1
anti-Sclerostin bone loss disorders phase 1
Oncology Indications Phase 1 Phase 2 Phase 3 Filed
CDP791 non-small-cell lung cancer phase 1
CMC544 non-Hodgkin’s lymphoma phase 1
Other Indications Phase 1 Phase 2 Phase 3 Filed
fesoterodine overactive bladder phase 1

Related links